Cardiovascular Health 2026

Key Takeaways

• Plaque volume doubled over ~5 years in low‑risk adults
• Non‑calcified plaque drove most of the increase, calcified stayed low
• Low‑attenuation plaque prevalence rose from 9% to 23% in cohort
• Half the participants had CAC zero yet accumulated soft plaque
• Study suggests early LDL‑C control may prevent silent plaque buildup

Pulse Analysis

Calcium scoring has become a cornerstone of cardiovascular risk assessment, yet its binary nature—zero versus non‑zero—can mask the early stages of atherogenesis. The NATURE-CT study, presented at the AHA Scientific Sessions, fills a critical knowledge gap by using serial coronary CT angiography to quantify plaque composition in a low‑risk, untreated cohort. By leveraging FDA‑cleared AI software, researchers captured volumetric changes in both calcified and non‑calcified lesions, revealing that a substantial portion of plaque growth occurs in forms invisible to traditional CAC scans.

The study’s headline finding—a near‑doubling of total plaque volume over roughly five years—was driven almost entirely by non‑calcified, lipid‑rich plaque, while calcified burden remained minimal. Low‑attenuation plaque, the phenotype most closely linked to rupture and myocardial infarction, surged from 9% to 23% of participants. These results suggest that even modest LDL‑C levels around 112 mg/dL can sustain silent plaque accumulation, challenging the practice of deferring lipid‑lowering therapy until a non‑zero CAC appears. Early intervention with statins or newer agents that target ApoB may therefore be essential for individuals focused on longevity and cardiovascular compression.

Beyond clinical practice, the findings spark debate about the generalizability of the data. The cohort was predominantly white males, and the abstract omitted multivariate adjustments for other lipid markers such as lipoprotein(a). Moreover, hard outcomes like myocardial infarction or mortality were not tracked, leaving a bridge to be built between volumetric progression and event risk. Future research should expand demographic diversity, integrate comprehensive lipid profiling, and link plaque dynamics to long‑term clinical endpoints. Until then, clinicians and patients alike should treat a zero CAC score as a snapshot, not a guarantee of cardiovascular health.